Disclosures for "First-in-Human Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAR443820, a Central Nervous System Penetrant RIPK1 Inhibitor in Healthy Participants")
-
Mrs. HINCELIN-MERY has nothing to disclose.
-
Pascale Lewanczyk has nothing to disclose.
-
Mrs. Cantalloube has received personal compensation for serving as an employee of Sanofi.
-
Mr. Nicolas has nothing to disclose.
-
Myriam Benamor has nothing to disclose.
-
Dr. Pomponio has received personal compensation for serving as an employee of Sanofi. Dr. Pomponio has stock in sanofi.
-
Dr. KRUPKA has nothing to disclose.
-
Dimitry Ofengeim has received personal compensation for serving as an employee of Sanofi. Dimitry Ofengeim has received stock or an ownership interest from Sanofi. Dimitry Ofengeim has received personal compensation in the range of $500-$4,999 for serving as a Study Section Reveiwer with NIH.
-
Dr. Eastenson has nothing to disclose.
-
Li Xiong has nothing to disclose.
-
Dr. Atassi has received personal compensation for serving as an employee of Sanofi. Dr. Atassi has stock in Sanofi.